Loading company…
ID 405104907 · FY 2018–2024 · 7 years
საქმიანობის ძირითადი მიმართულებაა მედიკამენტებით საბითუმო ვაჭრობა და მედიკამენტებთან დაკავშირებული საპრომოციო მომსახურება
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 34.7% | 32.6% | 21.8% | 28.8% | 39.7% | 30.4% | 41.7% |
| EBITDA Margin | 9.3% | 4.3% | 7.4% | 2.9% | 10.1% | 9.1% | 19.8% |
| EBITDAR | 463 | 279 | 716 | 230 | 581 | 623 | 1,362 |
| EBITDAR Margin | 10.3% | 5.8% | 7.7% | 3.3% | 10.6% | 9.5% | 20.2% |
| EBIT Margin | 9.3% | 4.3% | 7.4% | 2.8% | 9.8% | 8.9% | 19.6% |
| Net Profit Margin | 8.4% | 3.6% | 7.6% | 2.9% | 9.6% | 8.1% | 19.4% |
| Operating Expense % of Sales | 25.4% | 28.3% | 14.4% | 26.0% | 29.6% | 21.3% | 21.9% |
| Returns | |||||||
| Return on Assets (ROA) | 28.4% | 12.7% | 16.2% | 21.6% | 30.8% | 24.3% | 39.9% |
| Return on Equity (ROE) | 121.9% | 74.6% | 90.2% | 23.0% | 38.7% | 26.8% | 40.8% |
| ROIC [EBIT / Invested Capital] | 181.0% | N/A | 155.5% | 32.9% | 46.7% | 39.1% | 43.1% |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 23.3% | 17.0% | 17.9% | 93.8% | 79.4% | 90.9% | 97.8% |
| Net Debt | -80 | -320 | -342 | -282 | -210 | -471 | -139 |
| Cash & Equivalents | 80 | 320 | 342 | 282 | 210 | 471 | 139 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | N/A | 162.96x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | 2.2 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 3.66x | 4.65x | 2.35x | 12.90x | 4.13x | 5.53x | 2.35x |
| Days Sales Outstanding (DSO) | 99.7 | 78.5 | 155.3 | 28.3 | 88.3 | 65.9 | 155.1 |
| Payables Turnover | 2.91x | 2.84x | 2.04x | 84.83x | 9.35x | 23.02x | 54.10x |
| Days Payable Outstanding (DPO) | 125.4 | 128.3 | 178.9 | 4.3 | 39.0 | 15.9 | 6.7 |
| Cash Conversion Cycle | -25.7 days | -49.8 days | -21.4 days | 24.0 days | 49.2 days | 50.1 days | 148.3 days |
| Asset Turnover | 3.37x | 3.50x | 2.13x | 7.38x | 3.20x | 3.02x | 2.05x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | 265 | 465 | 75 | 91 | 27 | 398 | -265 |
| Free Cash Flow (OCF − Capex proxy) | 286 | 465 | 75 | 69 | -17 | 398 | -267 |
| Cash Conversion (OCF / EBITDA) | 63.7% | 225.2% | 10.9% | 46.3% | 4.8% | 66.5% | -19.8% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).